Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2019
Event: Entry into a Material Definitive Agreement to sell biomanufacturing and development assets.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics for the reporting period are not provided in this document.
- Asset Sale Price: $18.0 million total.
- Escrow Amount: $1.5 million (held for one year post-closing).
- Laboratory Supplies Fee: Approximately $0.4 million (subject to adjustments).
Material Changes
On June 26, 2019, Novavax entered into an asset purchase agreement with Paragon Bioservices, Inc. (a unit of Catalent Biologics). The Company agreed to sell assets related to biomanufacturing and development activities located at:
- 20 Firstfield Road, Gaithersburg, Maryland.
- 9920 Belward Campus Drive, Rockville, Maryland.
The transaction is expected to close in July 2019, subject to customary closing conditions.
Outlook, Management Commentary, and Risks
Post-Transaction Arrangements:
- Transition Services: Novavax will provide transition services to Paragon for a limited period.
- Manufacturing Services: Paragon will provide process and analytical development services to Novavax at preferred client pricing under a Non-Commercial GMP Manufacturing Services Agreement.
- Interim Services: Paragon will provide additional development and manufacturing services at time and materials pricing.
Risks and Contingencies:
- The transaction is subject to customary closing conditions.
- Representations and warranties in the agreement are qualified by confidential disclosure schedules and may not reflect the current state of facts.
- Information regarding the assets may change after the agreement date.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected July 2019).
- Confirm the final purchase price after adjustments to the laboratory supplies fee.
- Review the full text of the Asset Purchase Agreement (to be filed as an exhibit in a subsequent report) for detailed terms.
- Assess the impact of the asset sale on Novavax's future manufacturing capacity and reliance on Paragon for services.